Amneal Pharmaceuticals LLC has been granted approval for the ANDA040746 filing, securing the generic market for FDA-approved, oral-conditioned hydrocodone bitartrate and acetaminophen tablets. This regulatory clearance is expected to intensify price competition within the hydrocodone/APAP market, driving down costs for a widely utilized opioid analgesic.